-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
IGC Pharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2010 to 2023.
- IGC Pharma, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$1.76M, a 29.3% increase year-over-year.
- IGC Pharma, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$9.32M, a 14.5% increase year-over-year.
- IGC Pharma, Inc. annual Operating Income (Loss) for 2023 was -$9.8M, a 15.3% increase from 2022.
- IGC Pharma, Inc. annual Operating Income (Loss) for 2022 was -$11.6M, a 25% increase from 2021.
- IGC Pharma, Inc. annual Operating Income (Loss) for 2021 was -$15.4M, a 76.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)